Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wright claims US first for allograft bone graft pellets:

This article was originally published in Clinica

Executive Summary

The US FDA has given Wright Medical the go-ahead to market what promises to be an improved version of its Osteoset bone graft substitute. The Osteoset calcium sulfate pellets are now available in a form that contains human demineralised bone matrix (DBM) proteins. Osteoset with DBM have been shown to form natural bone architecture more rapidly than Osteoset calcium sulfate pellets alone, says the Arlington, Tennessee firm. Osteoset DBM joins Wright's Allomatrix putty - which received regulatory clearance in March - as the first FDA-cleared allograft-containing bone void fillers to become available in the US, the company claims.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057927

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel